<SEC-DOCUMENT>0001193125-23-104016.txt : 20230418
<SEC-HEADER>0001193125-23-104016.hdr.sgml : 20230418
<ACCEPTANCE-DATETIME>20230417210928
ACCESSION NUMBER:		0001193125-23-104016
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230417
FILED AS OF DATE:		20230418
DATE AS OF CHANGE:		20230417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23825280

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d497631d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated April 17, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d497631dex991.htm">Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April 17, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d497631dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g497631snap1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g497631g22o88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Initiation of Investigator-Initiated Phase II Trial in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Soft Tissue Sarcoma in Neoadjuvant Setting </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First time efti will be studied in neoadjuvant, <FONT STYLE="white-space:nowrap">non-metastatic</FONT> cancer
setting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel triple combination of efti with radiotherapy and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy has potential to generate a robust anti-tumour immune response </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY,
AUSTRALIA &#150; 17</B><B></B><B>&nbsp;April </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT
STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha (efti), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT>
protein and MHC Class&nbsp;II agonist, in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma (STS) patients in the neoadjuvant (prior to surgery) setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investigator-initiated study <FONT STYLE="white-space:nowrap">(EFTISARC-NEO)</FONT> will be primarily funded by the Maria Sk&#322;odowska-Curie National
Research Institute of Oncology with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. Immutep will provide efti at no cost as well as technical support. The trial will be led by <FONT
STYLE="white-space:nowrap">Co-Principal</FONT> Investigators, Katarzyna Kozak, M.D., Ph.D., and Pawe&#322; Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Sk&#322;odowska-Curie
National Research Institute of Oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Pawe&#322; Sobczuk, stated: &#147;We are excited to begin this chemotherapy-free study combining
radiotherapy with the novel immunotherapy, eftilagimod alpha, and pembrolizumab. Given efti&#146;s synergistic effects with immune checkpoint inhibitors and its ability to arm, activate, and proliferate cytotoxic T cells with radiotherapy-induced
cancer antigens, this combination has a strong foundation to drive effective immunity against soft tissue sarcoma, a rare and aggressive disease in immense need of new therapeutic approaches.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti&#146;s targeting and unique activation of antigen-presenting cells (e.g., dendritic cells, monocytes) via MHC Class&nbsp;II molecules leads to broad
adaptive and innate immunity to fight cancer, including proliferation of CD8+ cytotoxic T cells that can be armed with radiotherapy-induced tumour antigens. The combination of efti with radiotherapy and the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) has the potential to generate a robust anti-tumour immune response in the immunosuppressed tumour
microenvironment (TME) of STS. This is the first time efti will be tested in the neoadjuvant setting, which importantly will provide access to tumour tissue prior to and after treatment, where the impact of this novel triple combination on the TME
can be assessed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt added: &#147;Efti&#146;s unique potential to help safely drive superior clinical efficacy for cancer patients,
with and without the use of chemotherapy, is attracting increasing attention from industry and academia. We are delighted to see efti and pembrolizumab, which together have led to deep and durable responses in several
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> advanced solid tumours, being combined with radiotherapy for the first time and hope this approach can make a difference for soft tissue sarcoma
patients who have limited treatment options.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g497631snap1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g497631g22o88.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Soft tissue sarcoma (STS) represents a high unmet medical need with a poor prognosis for patients. The
incidence of STS varies in different regions, with approximately 23,400 cases annually and a crude incidence of 4.7 per 100,000 in Europe, according to the RARECARE project. In the United States, the number of new STS cases is estimated to be 13,400
annually with 5,140 deaths, according to the American Cancer Society. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dosing of the first patient is anticipated in the first half of calendar year
2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Maria Sk&#322;odowska-Curie National Research Institute of Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Maria Sk&#322;odowska Curie National Research Institute of Oncology is the leading Polish comprehensive cancer centre, as well as the primary government
research institution devoted solely to oncology. Founded in 1932 by Maria Sklodowska-Curie, it is currently divided into 28 specialised clinical departments responsible for the diagnostics and therapy of different tumour types such as: Breast Cancer
Clinic, Head and Neck Cancer Clinic, General and Visceral Surgery, Thoracic Surgery, Urology, Gynaecology, Haematology, Soft Tissue/Bone Sarcoma and Melanoma Clinic, Radiation Oncology, Brachytherapy and Diagnostic Radiology, Pathology and Molecular
Medicine and Cell Research, Oncology, Gastroenterology, Cancer Epidemiology and Prevention Division and others. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer.&nbsp;Efti binds to MHC II molecules on
APCs leading to activation/proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-y</FONT> and
CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g497631snap1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g497631g22o88.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g497631g22o88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g497631g22o88.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJO\ S\O^5%V'M9A_PD&J_P#/R_Y478>UF'_"0:K_ ,_+_E1=A[68?\)!JO\
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MJO\ S\O^5%V'M9A_PD&J_P#/R_Y478>UF'_"0:K_ ,_+_E1=A[68?\)!JO\
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A*NP?8K7_ )]HO^^!18.5=@^Q6O\ S[1?]\"BP<J['__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g497631snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g497631snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ME3]WI0!E>$/VRM?\(>%O#GA6U\':!>VWA[1=-T:"]?5KV)[B+3[2*V2=XUA
M1F6,$@  '..*-OD&WR/T&^$OCFZ^(WP^\.^,KJRM["YUJ.^>6RM)I);>W-KJ
MM]8(J32J&8-%;))SS\_'!% 'SI\9?VN=/\#:OJOA3P;I5MKNLZ6?L]]K.H7<
MD>A6=\IQ+9006A$VHSPYQ(1/:QJWR>8[*4 !XWHO[:WQ%TW4(?\ A+O"?AZ[
MT^4%_L]E!J^@7S0J-S-:S7U]?1RD*.&:#8?XG4<T ??OP\^(&A?$KPM9^*?#
M4TCVER7@EMKA-EWI]_  ;FRO(]W$L191D$*ZE74['% 'QE\0?VS_ !#HFOZ]
MX>\->"]*A;0-:U;0I;_6[^\U!;B?3-1GT\7"VVGI9K;I(UNS"-KB1CG[PVDD
M X33/VW/B3;W4?\ ;'ASP=?VS,K&"S@UG2[AX@0SF">;5[\;O+#89HG53@LI
M P38-C[9^#_QQ\*?&&QN6TI)]+UK3PIU+P]J,D,EY!&^ MS:2PG;?V!9@AF1
M4VM\CHAV[I:E>*6BUO\ A8/+IU1V'B#X;>"/$TIN-9\,Z5>W+,&:Z-M]GNV*
MGCS+NT,4T@_V7<BLOJM"<KU*:ER[:(\ZIE67UZG/7PT9M?W8_JC6\/\ A#PU
MX8A:'0="TW2E9=KM:6L233#.X^=<[3+/SS^\=JUC3A25J45%+LK?D=%#!87!
M_P"[48TO\,4GY;(Z4#  Z8 &.F,"J.F[^8M 'DGQQ_Y)9XL_Z\[3_P!.5C7/
MC/\ =JW]=3Q>(?\ D58OY?J>"?LG?\?OCG_KS\/?^A:K7DY+\%3_  Q_4^8X
M&_YCO2'_ *5,\H\;@-\=-00@$-X^TE6!Z%3?::C @8R"&Y!)&.HKDK5.3,%'
MEYDVSQL?3E/B?$VY;+$0NFO^G4?)GWUXM\.:5K?A;6=.O;*VFAETJ[";K>,F
M"1+9S%+ 0H\N6-U5D9<$%!Z5]!6A3GAFG32NET5]&M=#]*QF$HUL#4I2I0O[
M+XN5;Q2DGMY=_P -#X3_ &<8X9_B1917%M;7"S:)J89;FWCG6*:.*">*>%9%
M(BE41E-P&3O)R.E>1@52^M.G;X;].Q^=\+SHO/I4)T5.%*-9*ZBUI:VC6A]%
M_M(>&]/NOA_)K)MX%O\ 0]0L9;>X2%$F\F]N$L9X'D&&:)A<Q-@Y :!3CGCM
MS6A2EA9345%P2M\F?6<5T*/]DUJL*,8^Q5ERQBFKM+2R5OB_,Q/V5[J:3PKX
MEL"_[NSU]+J(8Z-?Z=$LHQGIOMPWUSP.M9Y/+FPT^G*VE]R?ZG)P/+_A/G'5
M*GB)JS_Z]TY?)>\>&:TBR?M 21L R/\ $;3D96&Y2K:K8*RLIZ@J2,5YTDO[
M12:YE[1:?,^=QBOQ2XZ+FK4%KMKRH^U_B1X9TK7/ WB6RN;.U8IHNH7EJY@3
M?:W5E:2W5O-"PPT96:%,A2N1N!X-?08B$/85_P!VM(]E_*_R/T'-,'1JY;BX
MJE3C.G1DU+E72#?17/D']FC[/+\0KZUN;6UN$D\.:A<1>?!%(UO+;:CIBK+"
M70^7(4E<$IMSGVKP,JJ*IB6ITETM=)GPO!SC4Q]2T8RMR_$D^^VC/;OVEO#^
MFW/@2/7!:PQZAI6J62174<<<<YM;LR0SVS2!<M$[-&VUMV"@(P<FO5S.E25!
MVBHM7V270^@XOPE-9?/$J$8U*,XVY4EI=M:I+6Z*/[*=S-)X4\26KR%XK3Q"
MKP@Y^3[5IUE)*.2>6E1G.,<N>/7'*)2]E*+V3T_ C@MR_L^O">].O*WHZ=+_
M .1/A[P<VW]J.U&.GQ?U?V_YF.]_PKV#[$_8J@#\>_V6/^2^>%?^N/BK_P!1
MW4Z /1OVXA_Q7WA$#C_BC4'?H=:U@'@$=LT ?;GP8T?29_A)\-IIM+TV6:;P
M3X<DEEDL+5Y'D?2K9F=W:(EF))))S0!K_%+63X)^%_C37=.6&UGT;PWJEQI_
MD0K%%#?O!)':2I%%@#;>S12;01\R]><T ?E5\!?&/PX\ ^,+WQ-\1-/U'5I+
M.TB7P]%:V5KJ9CU669S<ZE=QWE[;K)<):KMCD.\[[B1^'VD&P;'T;\9/VC?@
MK\3/ 6M^'!H_B5M9:TDF\-WEYH>FQ_V?K,"^99R+<QZK(\$;LIAD"JRLDS*5
M.: ,_P#89U6\CU[QSH#SR_8Y=+TO6(K4LWEPW5G=O822A !\TD%_"ASU%K%G
M=LS0!Y+X$B2;]J_RI$1T;XM^,25D7>AV:IK[@,C?*PRHZ@X(!'3D _57Q%X.
M\->*])O-&\0:/8:EI]W;RV[Q7-K#*T*.CIYEM)(C-;7";MR2Q%75E4@Y P ?
MDGX%EN_@_P#M#V&DV=S)+%I'CIO!<\CX#WNCZCJ;Z(QE*YZPS6UP4Y'FP*Y)
M(X-@V/V3' ],9Z<8YH 6@ H * /)/CC_ ,DL\6?]>=I_Z<K&N?&?[M6_KJ>+
MQ#_R*L7\OU/!/V3O^/WQS_UY^'O_ $+5:\G)?@J?X8_J?,<#?\QWI#_TJ9Y3
MXV'_ !?>^_['_1_TU#2JYZFF/A;3WV>-C4GQ7B;I.U:/3_IU$_1G5.-*U#L!
MI]T/3'^CN!7T-;2%5=%%Z>A^I5%;#5.EJ+M_X ?GK^S<1_PLS3,<'^R=5]O^
M7,5\[E2_VW77W*GWH_-N'$HYVN5<KE[:[6C>^]MSZL_:#_Y)5XB_Z[:/^FMV
M./Y"O5S+3!3Z:?J?8<4-QR7&6?+\.VGVH'FO[*7_ "!_&(]-4TO\OL<M<^1_
M[M6\IR_])B>9P7)O!UKMMK$2W?\ TYI'C6K#'[0?T^).F?IJVGUPS;68JVEJ
MD?S/FL4D^+81:O'ZSAM'M\<+:,^^O%H'_"+>)>!QX=UKL.,:9/C\LG\Z^CJM
M^PK:_9_]M9^F8^*^IXF-E9X>M=6TTIM*Z\EHNQ\,_LS8_P"%F2\#Y?"^K@<=
M!]MT@\>G/-?/Y2W]9>O8_.^#8Q68*T4O<OMUUU/H_P#:1 'PMU#C'_$WT,>G
M!OXP1]*]3-5;#2Z-)V^X^NXG2_L>IIO.G?\ $X?]D]MGASQ<?37K7 Z9QI5O
M@?I7/DK?L)>3_1'G<%MO"YC=M\N(BE?HO9K1=CX>\0S2?"_]H[4]5U:*9K?0
MOB4_B"=(XR9WT:]U<:MYD0;[QETV_C6-L@;QZU[.Q]IL?KMI?B?0-7TJ'7M.
MUK3[O1KBW2XBOHKF$VWELH<,9"W[I@IPR.0RE2"!0!^3?[+ /_"_/"V!D+#X
MISCD#/AS4\<CCG(H ]._;CMI4\:^"+L9\N]\,7=O <+S)I^J.\R*'!'*ZC <
M#D;R<9- 'V#^SSXKT'6?@WX%^Q:E:,^A>&]-T75(GN$66PO-)MH[*=+H.X*9
M\D2!SPRRJP.&H_0/T.F^(5C8?$;X7>,](T.]M-136=!UNPL+BTF2>!]3M%N8
M[>,21$@E=4LQ&<=T(% 'Y>?L]ZA\,=.\8:EH_P 5]&TVZTG5+>&ST^\UJUDN
M(M#UBTNV'EW3@DVZ74<SPO(RA5DM8PY )P ?I$/@M\!FLQJ \$>"CI[('^VF
M*V%IY9"N&-P9?+"XVGEO2@#<^'/A?X3Z<EUK_P ,M*\-6\5S)/I5WJGAY5\N
M<V<ZBXLVGB)27R[H+N4$C<!_$* /S&\-:SIGAW]IVZUK6;V'3-*L/BSXN>\O
M[@[+>UCDU?7H5::0C$:F1U7/O[' !^K?B'Q[X0\,^'+CQ1JVOZ9!HL-JUREV
MEU%(MTI4F*.S6)RUQ+*V$18\EF8"@#\G_AY#=_%[]H?3-4BMQ:)JOC:X\;74
M#.TCV>EZ7J3ZV\#R+G:ZP0VUJ0.#),N>9.3] _0_9%<A1G&0!G'3('./;- "
MT % !0!QOC[PQ)XP\):QX:BO$L)-3@BB6ZDB:=(3#<P7&3$LB%L^3M^^,;L\
MXP<ZU/VM*=._+S=;7M\M/S.+,,']>PM7"^T]C[2WO<O-:W]WFC?[T>>?"#X1
MW'PRFUV:77;?61K,.G0JL%C):?9_[/-T6)+7,WF;C=8QA<>7U.>.3!8'ZDI+
MVOM.9)?#R[?]O2/+R/(?[%]O_M7UGVRBOX7L^6S;_P"?D[[^6QR.O?L^WNK?
M$"?QI'XJM+:&;Q#9ZX=.?2IGE1;2XM9_LWGB]49;[+M\S8 -^=IVX.<LMYL1
M&O[:W++FY>3\+\WZ''6X7]KFM3,_KW+SS4_9>QO:T%&W/[57VO?D7;S/I:\@
M^T6-Q &"^?;20JWRD*94*!OO $#<#P>>V:]&<>925[<R:^\^IE3YJ4J=[<T'
M"]O[MKVO^%_F?.'PQ^ =Y\/?%5IX@F\36VJ);V=W:_98M,DM787,/DB0R27L
MFT+C.-ASTSWKSL)EOU2O[;VW/927+R6^+SYGMZ'S67<-?4,<L9]=]KR\_N>Q
MY/CO]KVLMK_RZ^1Z]\1O!TOCKPCJ7AF"_33);][)UNY+=KI(OLE_;WC PK-&
M6W+"5^^,$@^U=6)P_P!8H.CS\E^MK_A=?F>QFF _M+!5L'[7V'M;>_R\]K.+
M^'FC?X?YEN<O\(OA=<_#&SUJUN=8BU@ZK=6ERCPV3V/DBUA:+RRCW,WF;M^<
MY7&,8/;/ X/ZE2G2]I[3F;=^7EMHEMS2[=SER7)_['HSI?6/K'-4=2_L_9VO
M"$+6YY[<E[WZVMI=\1>? .^NOB+_ ,)T/$]LL/\ PD]KX@_LLZ5.9!';7=O=
M?9?M2W>-Q\C;YGE8&[.WC!PEEE\1[?VUK24N7D[>?-^AYU3A?VF;QS3Z]R\M
M6G4]E['_ )]N+MS^U6]K7Y-.S/H?6+%M3TG5-,200M?Z;?6"RLI=86N[5[=9
M"@P7"[]Q4$'C&1UKT90YH3A>W,K7[:-;'TU>E[>E4I<W+STYT[VO;GBXWM=7
MMO:ZOW1X'\+/@1>_#OQ2WB&?Q-;:K&VE7FFBTBTN6S<?:IK.83>:][*,+]DQ
MLV\^9G<-N#Y^$R[ZI5]I[;GVTY+;>?,_R/G<FX;_ +(Q"K_7?;VCR\OL?9]]
M;^UGW['IOQ/\$S>/_"=QX:@OX],>>\L+H7<ENURJ"RN%G9/)26,G<%QG>,9S
M@XQ77BL/]9I.ES\E[ZVOY;77YGKYIE_]HX.6$]K[#FE&7/R\_P /3EYH_F87
MP?\ AC-\,M,UBPFUB'6#JFH0WRR0V;V8M_)MHK;RF1KB;>28MV0R]<8XR<L%
M@_J5-T_:>TN[WY>7LMN:78YLDR?^QJ6)I?6/K'MZBJ7]G[/EM%1M;GG?:][K
MT.-^-O[.'ASXLS1ZY!?/X>\6P00VO]K);)>V=_:6[ QPZI9,T;,\:;DCNH9(
MY$!"/YD8\NNW]#VOT/ET?L.>-@^!XU\+-;94AOL^K(2206<PFW*@''3>YSC)
M.*-O(-O(]J^#?[*5Q\,O&>F^-=1\:0ZO=:7#?QPZ;9:$;6!VU#3KC3I6DOKB
M^E?:D=P658X(_N <9R#8-CV[XP?!_P /_%WPXFCZO++I^H6$[7FB:W:1Q/<Z
M9>,A1P\4I"W5A,JQ":W+Q[_*5ED214=3] _0^*S^PYXSBF98/'/AEK4AD-PU
MCJL4K* 0I>U$<J\,0=IN&^X!O]#8-C[3^"GPSN_A3X)B\)7FOCQ#Y6IWVHQ7
M$=A_9]M:K?>3(]E;0&ZN"8$N5GE5RT9S<,-@QDFP;'C7Q=_9*T#QUK-WXG\+
M:P/">N:C,;G5+:XLQ?:'?S$(&F@MX9H9M,NY77?,\?GQ2EB3 &+%C;Y!M\CP
MZ/\ 8=\<%UCG\:>%X[9<*K0V^KRN$7HPMVLT7<0<X:3&>]&WD&WD?:OP2^%L
MWPB\%GPI-KQU]VU>]U;[4NGC3(X/M<=I']DA@%U<%HU-J7+M)EFG;Y5 Q1L&
MQ^6C>$HO'7Q^\0^$)KY]-CU[XE>-;#[;'#'<-:L=6UR>.;R)9HEF19($#)O4
MLK$ CN >]-^PSXO,R1CQ[X;-HC?Z\:9JL4VPL-SI8QOL!*9.W[25SCGC- 'U
MU\&?@-X6^$%C<R6$TNL>(]2BCAU3Q#=PQ0RR1QL6%KIMM%(_]G6&=C&+S9)'
M>,/+(V%5#;Y!M\CW8#: ./EXX& ,= !V H 6@ H * ,C6M2CTBSCNY8GE5K_
M $K3PD;K&P?5]5LM)B?<^!M26]1R,@D(0.: )=6U"#2-*U#4[@,8=/LKF\E6
M)<R.MM$TICA4XW3/M"HN069E /- '.0>,+3_ (127Q1J-I<Z6MG%<IJ6E2/#
M<7]GJMI<2V-SHP:V<QW%XNI1FUB,9*3%XGC;8ZM0!J:1?ZU=L!JNB+I2- DR
M*-5M]1ECD?)>SNXX+:-(KF(8W&WENH<DA96 4D K^*M>D\.:=)JBVMM/;6EO
M=SW376J)I:JL,:M'!;B2WE^U7]Q(!%!$1&K.0K2IO&X Z.-_,ACE56!9$<(Z
MF-P64-M=2/W;#H0>AR.U 'G>J?$?2](T7PCK=]:W<-IXLO[>P0AX"=)CFTN_
MU6?4;[,B[K*UMM,N'F:,,50%\!4:@#=7Q/;S^*I?"D-K=O-!I$NIRZBJQ&PB
MEAETQ'TW)D$C7Z6NL:==LHC:-8;J+)+2JM '+)\4M*'A;7O$QTS5%_L35M2T
MA-'"V[ZEJ5Q97#PV<E@JS&)K>]MX_M$<C.@2%93*5:"3: ==)XC@3Q)I7AU(
M9Y3JWA[6O$$5ZNT6\<&D7F@V1B885]\IUR-UP.D3'- &/JOCJWTO1H-9?2=2
MNXI/%%WX:>UL_)FNXWT_6M3TFYU#RRZ^=;Q_V9/<F*+?*T1 178%: +=UXUT
M6UM=7U%KE7T;1_#.G^+9]7M7%W9S:1?KK$B3VGV=MTR"'19G7RRPD\^,+R20
M 5(O%U_!=Z%%K?A^;1[?Q%.EE871OX+N2UU"2![BVL-7MXX$_L^>>*!Q&89;
MR+S&$;2!F4, 30>)M6E\3R^&6T*&-[>P@U:6Z_MG<O\ 9MSJ%S8P3)#_ &=_
MKV>RE;R/-&U3@R \$ ED\9Z?#;:]<2QF.70=3?3);1KFU6XN)%2Q=9(5#\(R
MWHPK?,?+/'2@"6]\275MKC:):6-I<R0Z?IFH3R76KQ:=^[U2]U2SBBM87M93
M=2QG2+AVPZ_ZQ%QEL@ K:[XJNM(N=6BM=&?4H]"T.PU_4F34;:SF%E=W&LP[
M;..YB$<\D*Z%=2.)9H!ME0!BQQ0!)KOB^#1O#MKKUMI^HZN;];$:?I5FD<>I
M7IO8#=D(MR\:H\-A'<74@8A@EG*%!; ( W4_%T%I'X5DTJ!-8/C"_2STF5;E
MK2S>-M%U'7UO99_(G=+<V.ESD*(B271>,' !GP^.XFLK>_N=)O+.%/$T_A?6
MS/=V3PZ)<6K2PK?331RE+K2FNVM4-Q!\T:W223JB0RA #J-!UF+7+:>\M89T
ML$O9[2RNI1L34H;8K%)?6L;?-]C:[%Q''*0HF6W\Z/=#-$S@'Y2^ /\ D[-?
M;XM>,S_Y4?$6* /UX &!QT_2@!<8]OTZ4 % !0 4 % &+K^E/K&G?8HKE;25
M+[2=0AG> W$:SZ1JUCJT"2P+/"9(GFL41E66,[6.#D4 8VI^&KSQ!I*Z3K.K
M((9-0L[J[ET6"]TF:XMK&YBO(;2*Z.LW%U9.;J"!FEAG!V*\0 $A( ,>V^&>
MDVFG^)=(CO-7?3/$<UK?RI?:I>:K>V>M6L4$::M:ZAJD]Q.TX?3]*G59GE"3
M6)?YO.90;!L;%GX=U%M:&JZSJ]O?HNA7.A1V-IITNGVLD-W=6UU-=W44NJW2
MRW.+81*8TA 25P  <  DU3PNEQIL>BZ:-%LM*\F:&6QO]#&JP%9  DEO#_:-
MK'',A,C!YDN>6& H#!P#I+*U%C96MG'+-.+2WAMTFN7\R>801+$LD\G'F2L%
MW,V!DDGO0!QC>!;&6T\'6-W(MW:^$OM86WN;>&6'4%O=!U+P^ZW4;@CRS:ZI
M<[E&0P9D(VL: )] \$6/AF;3)-/N;R8:=8ZY9O)J4_VR]OFUN[T>[DN;N[(4
MRRPC1;:"/Y1B *G_ "S3 !F0_#;2HDMBUY?-<0:+?:1M#Q"QN)+W^TU759K/
MR_FU*WAUG5X89!(%6/49E97^0H 79/!\\=WX<U6QU18-8\/:%>^'DGO+%;VS
MO]/U!-(-WY]K%=6CPW!N=#L)4>&X0*1*I1Q)\H!,OA!1INCV,NHRSS:7XDE\
M33W(AAM_ME_=:C?ZK>CR(6VV\+W>I7&Q58LB;5+.068 HM\.='=/%UA+<7KZ
M/XPTU-+GTU9(XX]+@,FL7%TFDRQP[[:)[G6;JX2-RZPRL1'MB*Q( 6?^$4U"
M]N=%DUO73?VV@7\>JVEO:6!T^2_U&WANH;6XUJ9KVY6=8_MDL_DVD-DK3QPL
MW[J(0T ;::$D7B>X\2"9VDGT*RT-K;"[$CL;^^OUG#9SYC/>LA7H @/4F@#$
MN/ >DW,/B#SH;62\US5'U07\EE:R75E)Y-E%&EO.\9D78MD"#NR#(<=* )M3
M\+S7>O/KMO)HAEETW2]/,>L: =5>W.E7NKWD4]C.-4M3:N[:O*&_=OS;Q,.X
MH AU_P  Z)XENM1N]7@@GFO=)TG3+>X%K ;K3)M)O-6OHKS3YYDD:*5KC5%)
MC.Z-A9QAUD5G4@":KX(&OW.AW&LZSJV[1+*XBC30K_4O#:RZG>)'#=ZJ9M*O
M8IT;[,DL$4 F*1QWUROS[@5 ,^/X9:.ECX2TAW-UI'@_7K[5M.L-0B6_1K6X
MT[7M.L]+F>[,AE@M(=>E6.1]SLEI"LA;YF8V\@V\CK+SPYIDNA:AH%K:6EA8
MW]C=V/D6MI;Q6\8O(I(G<6Z1B,MNE9SE?F;ELT :.F6,>F:;I^G1']WIUC:V
M,>$6,%+.".W0A%PJ#;&, 8 Z#B@#YAT/]ES2M#^*(^)\?B[4;F['BC5_$XTE
M]-LTMA-JUQ?W$EI]I6[W^7&;]P&V9/EKD<FC8-CZM' ';';T_*@!: "@ H *
M "@ Q^G3VH /Z?IB@ Q^GZ8H 3 ]!QT]J %_S^5 !C''0#C'3&/:@!, =L8_
M#&* # '8#].E !@>@R/;I0 O3VQ^&* $P!V /T ]OY 4 & .P'X8H ,#T''M
MTQ0 8'H..1QTH , =L?ITH   .@Q].* %P/3IS]"./Y4 ( !T &..!C '04
C+0 F!Z#C],4 +0 =/;'X8Q0 =/;'X8H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
